2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Ming Lung Yu; Pei Jer Chen; Chia Yen Dai; Tsung Hui Hu; Chung Feng Huang; Yi Hsiang Huang; Chao Hung Hung; Chun Yen Lin; Chen Hua Liu; Chun Jen Liu; Cheng Yuan Peng; Han Chieh Lin; Jia Horng Kao; Wan Long Chuang

doi:10.1016/j.jfma.2020.04.003

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Ming Lung Yu^*, Pei Jer Chen, Chia Yen Dai, Tsung Hui Hu, Chung Feng Huang, Yi Hsiang Huang, Chao Hung Hung, Chun Yen Lin, Chen Hua Liu, Chun Jen Liu, Cheng Yuan Peng, Han Chieh Lin, Jia Horng Kao, Wan Long Chuang

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

66 Scopus citations

Abstract

Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.

Original language	English
Pages (from-to)	1019-1040
Number of pages	22
Journal	Journal of the Formosan Medical Association
Volume	119
Issue number	6
DOIs	https://doi.org/10.1016/j.jfma.2020.04.003
State	Published - 06 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2020 Formosan Medical Association

Keywords

Consensus
DAA
HCV
TASL
Taiwan

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jfma.2020.04.003

Cite this

Yu, M. L., Chen, P. J., Dai, C. Y., Hu, T. H., Huang, C. F., Huang, Y. H., Hung, C. H., Lin, C. Y., Liu, C. H., Liu, C. J., Peng, C. Y., Lin, H. C., Kao, J. H., & Chuang, W. L. (2020). 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association, 119(6), 1019-1040. https://doi.org/10.1016/j.jfma.2020.04.003

@article{84e32ac870a64c6bb7e6d743ac10b53a,

title = "2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population",

abstract = "Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.",

keywords = "Consensus, DAA, HCV, TASL, Taiwan",

author = "Yu, {Ming Lung} and Chen, {Pei Jer} and Dai, {Chia Yen} and Hu, {Tsung Hui} and Huang, {Chung Feng} and Huang, {Yi Hsiang} and Hung, {Chao Hung} and Lin, {Chun Yen} and Liu, {Chen Hua} and Liu, {Chun Jen} and Peng, {Cheng Yuan} and Lin, {Han Chieh} and Kao, {Jia Horng} and Chuang, {Wan Long}",

note = "Publisher Copyright: {\textcopyright} 2020 Formosan Medical Association",

year = "2020",

month = jun,

doi = "10.1016/j.jfma.2020.04.003",

language = "英语",

volume = "119",

pages = "1019--1040",

journal = "Journal of the Formosan Medical Association",

issn = "0929-6646",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - 2020 Taiwan consensus statement on the management of hepatitis C

T2 - part (I) general population

AU - Yu, Ming Lung

AU - Chen, Pei Jer

AU - Dai, Chia Yen

AU - Hu, Tsung Hui

AU - Huang, Chung Feng

AU - Huang, Yi Hsiang

AU - Hung, Chao Hung

AU - Lin, Chun Yen

AU - Liu, Chen Hua

AU - Liu, Chun Jen

AU - Peng, Cheng Yuan

AU - Lin, Han Chieh

AU - Kao, Jia Horng

AU - Chuang, Wan Long

PY - 2020/6

Y1 - 2020/6

N2 - Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.

AB - Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy, excellent safety profile, and truncated treatment duration, has revolutionized the paradigm of hepatitis C treatment and made HCV elimination possible. To provide timely guidance for optimal hepatitis C management, the Taiwan Association for the Study of the Liver (TASL) established an expert panel to publish a 2-part consensus statement on the management of hepatitis C in the DAA era. After comprehensive literature review and a consensus meeting, patient-oriented, genotype-guided recommendations on hepatitis C treatment for the general and special populations have been provided based on the latest indications and scientific evidence. In the first part of this consensus, we present the epidemiology and treatment situation of hepatitis C in Taiwan, the development of DAA, pre-treatment evaluation, post sustained virologic response (SVR) monitoring, and most importantly the treatment recommendations for the general population with compensated liver disease. The second part will focus on the treatment recommendations for the special populations.

KW - Consensus

KW - DAA

KW - HCV

KW - TASL

KW - Taiwan

UR - http://www.scopus.com/inward/record.url?scp=85083846716&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2020.04.003

DO - 10.1016/j.jfma.2020.04.003

M3 - 文章

C2 - 32359879

AN - SCOPUS:85083846716

SN - 0929-6646

VL - 119

SP - 1019

EP - 1040

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

IS - 6

ER -

2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this